Many patients use supplements, and recent studies have addressed their impact on LDL-C. Current evidence shows no relevant effect of diet composition on LDL cholesterol. The class III recommendation is an important novel part of the 2025 Updated Guidelines. Read more here: eas.to/guidelines-2...

The EAS Advanced Courses on Rare Lipid Disorders continue their mission. On November 28, we welcome you to Berlin for the next course, hosted in collaboration with our German colleagues. Find full details and register here: www.dach-praevention.eu/eas-course/

Discover the EAS LatAm Chapter and connect with their representatives. Gain first-hand insights from them on the Focused Update of the ESC/EAS Guidelines for the management of dyslipidaemias: eas.to/guidelines-2...

Kitty Almer tells us about the importance of high-level events such as last week’s in Brussels, emphasizing that evidence must be taken into account in policymaking.

Great mentors and researchers shape the future of science. Two weeks remain to nominate for the Anitschkow Prize 2026. Think of the mentor or researcher who inspired you - now is your chance to give them the recognition they deserve: eas.to/Anitschkow20...

Don’t miss your chance to join the Advanced Course on non-classical risk factors in Vienna, October 27! This is not your typical course. Limited places available – once we’re full, that’s it. The next opportunity like this may be a long way off. Secure your spot now: eas.to/NCRFATReg

Happening Today – Don’t Miss It! Join the @eassociety.bsky.social webinar at 17:00 CET to explore the latest Lp(a) guidelines with Dr. Koskinas and Prof. @LaleTokgozoglu. Bring your questions and join the live Q&A—we can’t wait to connect with you online 💫 Rego: eas.to/WebSep29Reg #EASSoMe #CvPrev

Join us today at 17:00 CET for an insightful webinar exploring the latest Lipoprotein(a)-related guideline recommendations. You can still register here: eas.to/WebSep29Reg

Feeling honored to be recognized for the 3rd consecutive year on Stanford University and Elsevier’s Top 2% Scientists list. #Grateful to my incredible colleagues and mentors — thank you for your support as we keep pushing boundaries and growing together @unibo.it @eassociety.bsky.social #CvPrev

Prof. Mafalda Bourbon shares the outcomes of the high-level event at the European Parliament. She notes the solidarity across our community - patients, clinicians, and scientists - along with the goodwill of the MEP Group, and underlines prevention priorities, including FH screening for children.

Prof. Børge Nordestgaard emphasized that patients must be at the centre of the upcoming EU CV Health Plan, and our society supports them with evidence. Yesterday, their voices were heard through short, emotional testimonies that humanised the stakes of missed or late diagnoses. We are proud of you!

The EU High-Level Event on cardiovascular health is happening right now at the European Parliament 🇪🇺. Patients, policymakers & experts are coming together to highlight why early screening for FH and Lp(a) must become a European priority.

From evidence to policy – and from policy to practice! Our work goes beyond generating scientific evidence. We share the knowledge with policymakers to help shape stronger cardiovascular health strategies at the European level. You are warmly invited to join the meeting online: eas.to/EP25SepReg

Certain cancers increase CVD risk, partly beyond traditional risk factors. Earlier guidelines gave no advice on lipid lowering in survivors, but new evidence now allows updated recommendations. Read more here: eas.to/guidelines-2...

It’s FH Awareness Day! ♥️ We’re celebrating with you during our webinar this afternoon. Who’s joining us? If you haven’t registered yet, this is your last chance: eas.to/WebSep24Reg

🌍 It's FH Awareness Week! Early detection of Familial Hypercholesterolemia can save lives. 🎙️ Check out our special #AtheroTalk episode to learn about this underdiagnosed condition and help spread the word. Spotify: open.spotify.com/episode/5npU... @eassociety.bsky.social #cardiosky

We're launching the first online version of the Rare Lipid Disorder Course as part of FH Awareness Week 2025! This self-paced, multilingual course is designed to improve global access to expert knowledge on rare lipid disorders, building on successful live courses. eas-society.org/course/onlin...

Listen to this special FH Awareness Week episode of AtheroTalk featuring Prof. Steve Humphries. He shares valuable insights into familial hypercholesterolaemia (FH) and introduces the newly established EAS Paediatric Lipid Working Group. 🎧 eas.to/ATHTalkE18S 🎧 eas.to/ATHTalkE18A 🎧 eas.to/ATHTalkE18Y

🚨 Join us for EAS FH Week 2025! FH is still underdiagnosed and undertreated - it’s time for action. Together, we’re raising awareness, shaping policy, and driving better care: eas.to/FHWeek2025

EAS President Prof. Børge Nordestgaard will speak at the European Parliament on 25 September 2025, alongside Profs. Albert Wiegman and Florian Kronenberg, at a high-level meeting on advancing cardiovascular prevention, hosted by MEPs Romana Jerković and Tomislav Sokol.

People with HIV have double the ASCVD risk, leading to a 2019 Class IIa recommendation for statins in dyslipidaemia. After the REPRIEVE trial, 2025 guidelines now give a Class I recommendation for statins in all ≥40-year-olds with HIV. Read more: eas.to/guidelines-2...

Cycling to work refreshes my brain and improves cardiovascular health! It is also super beautiful if you work in #Helsinki @eassociety.bsky.social #cholesterol #cvd

Do you know an outstanding scientist whose work has significantly advanced the field of atherosclerosis and cardiovascular research? We are now accepting nominations for the 2026 Anitschkow Prize! This is your chance to highlight and honor a colleague, mentor, or peer: eas.to/Anitschkow20...

We’re thrilled to welcome Marwa Sadik, HoFH Patient Ambassador, as a special guest at our upcoming FH Week webinar. Marwa will share her powerful personal journey with homozygous familial hypercholesterolemia, offering valuable insights into living with this rare condition. eas.to/WebSep24Reg

In this episode of AtheroTalk, we explore a new Consensus Statement that proposes a three-stage, holistic framework for understanding and managing metabolic disease. 🎧 eas.to/ATHTalkE17S 🎧 eas.to/ATHTalkE17A 🎧 eas.to/ATHTalkE17Y

High-dose icosapent ethyl is now recommended for high-risk patients with elevated triglycerides, based on REDUCE-IT, while volanesorsen is advised for FCS patients to reduce triglycerides and pancreatitis risk, per the APPROACH trial. Read more here: eas.to/guidelines-2...

It’s unclear if lowering Lp(a) reduces ASCVD or AVS risk, so managing other risk factors and lowering LDL-C remains key. Despite earlier concerns, statins don’t raise Lp(a), and high-risk patients should still use high-intensity statins: eas.to/guidelines-2...

The European Lipoprotein Club Meeting #ELC is special! Great to be back, meeting friends and discussing our latest data from www.moncytehealth.com! @eassociety.bsky.social @barteltlab.bsky.social

Prof. Šekib Sokolović emphasizes the importance of proper dissemination of the Focused Update of the 2019 ESC/EAS Guidelines at local levels. Learn more about the key messages yourself: eas.to/guidelines-2...

Join us for a special session in recognition of Familial Hypercholesterolaemia (FH) Awareness Week. This webinar features the recorded session from EAS 2025 in Glasgow, highlighting key insights into FH diagnosis, treatment, and global strategies. Register here: eas.to/WebSep24Reg

The Task Force recommends early and intensive LDL-C lowering in all ACS patients, starting with immediate statin therapy as appropriate. Follow-up lipid checks at 4–6 weeks and life-long treatment to reach LDL-C targets are strongly advised. Learn more: eas.to/guidelines-2...

The 48th meeting of the European Lipoprotein Club starts today! The European Lipoprotein Club (ELC) is a worldwide network of basic scientists and clinicians involved or interested in lipoprotein research. To learn more about this year's programme, click here: eas.to/elc25-agenda

Join us in Milan on October 30, for the EAS Advanced Course on non-classical risk factors. This full-day event brings together leading experts to explore emerging topics in cardiovascular science - including MASLD, cardio-renal syndrome, inflammation, and gender medicine. 📋 eas.to/NCRFITReg

As soon as the 2025 Focused Update was published, we invited representatives from the National Societies to share their thoughts. Hear from Prof. Pablo Corral as he speaks directly to our Latin American audience. Learn more about the key messages from this publication: eas.to/guidelines-2...

What is new regarding LDL-C lowering therapies?: eas.to/guidelines-2.... The Task Force advises adding non-statin drugs like ezetimibe, PCSK9 inhibitors, or bempedoic acid if statins alone don’t reach LDL-C goals. Choice depends on needed LDL-C reduction, patient preference, availability, and cost.

Listen to Prof. Borge Nordestgaard explain the new recommendations on statin therapy. The update provides clear guidance on primary prevention with statins. Click here: eas.to/guidelines-2...

The European Atherosclerosis Society is now accepting nominations for the 2026 Anitschkow Prize, honouring researchers who have made outstanding contributions to the understanding of atherosclerosis and metabolic disturbances. Submit your nominations today: eas.to/Anitschkow20...

It was great to present our latest data at #ESC Congress in #Madrid and to catch up with colleagues and friends at one of the most important cardiology conferences! Huge event with great science and clinical data + Madrid is a nice city! @eassociety.bsky.social #moncyte-health #cholesterol #CVD

The Focused Update recommends risk-based LDL-C lowering, highlights greater benefit in youth, and adopts SCORE2 and SCORE2-OP to estimate both fatal and non-fatal events up to age 89, with risk thresholds roughly doubled to reflect higher non-fatal event rates. eas.to/guidelines-2...

We are pleased to announce that the European Society of Cardiology (ESC), together with the European Atherosclerosis Society (EAS), has published the 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias: eas.to/guidelines-2...

🔥 Hot of the press our printed program big thanks to @albamena.bsky.social & our sponsors @eassociety.bsky.social @dfg.de Menarini Group @sablesys.bsky.social TSE Systems Agilent Technologies @lucidscientific.bsky.social Biosfer Teslab More info: eas-elc.org

Don’t miss the opportunity to expand your knowledge of non-classical risk factors for cardiovascular disease! The next course takes place in Vienna on October 27, bringing together the scientific and medical community. Check the programme on the banner and register today: eas.to/NCRFATReg

Grateful to @TouchCardio for the kind invitation to be interviewed. Many thanks to @eassociety.bsky.social and the whole Touch Cardio team for the opportunity, it was a real privilege. #CardioSky Link: touchcardio.com/insight/qa-w...

The LatAm webinar series has arrived, and the waiting time is over! Join us today at 18:00 CET to learn more about cardiovascular kidney metabolic syndrome through a case-based presentation. This is your last chance to register for the event with Spanish subtitles provided: eas.to/LatAmWeb1Reg...

ESC Congress 2025 begins this Friday! EAS is delighted to contribute to the scientific programme with key sessions. Discover what’s coming up soon: www.escardio.org/Congresses-E...

It was very nice recording this podcast and talking about our research at @helsinki.fi and forming the startup company www.moncytehealth.com!

Big thanks to sustained support by @eassociety.bsky.social & @dfg.de and our sponsors Menarini Group @sablesys.bsky.social TSE Systems Agilent Technologies @lucidscientific.bsky.social Biosfer Teslab and the Italian 🇮🇹 Society for Atherosclerosis Research!

Our Certificate is gaining more and more attention! With practical tips from clinicians, researchers, nurses, and patients, you’ll strengthen your knowledge of lipid disorders, and contribute to truly patient-centred care. Join the course today! eas.to/CertNurHCP2024

@spfisterer.bsky.social, was our guest in the latest episode of AtheroTalk. We talk about his academic journey, his move into biotech, and his vision for the future of precision medicine in atherosclerosis. 🎧 eas.to/ATHTalkE16S 🎧 eas.to/ATHTalkE16A 🎧 eas.to/ATHTalkE16Y

Join us in Gothenburg on October 17! If you’re nearby, don’t miss the chance to register for our first event in the series. Our aim is to raise awareness and increase understanding of non-classical risk factors for cardiovascular disease. Register today and secure your spot: eas.to/NCRFSWEReg